The use of CAR T-cells targeted against MUC1 is proposed for relapsed or refractory solid tumors like glioma, metastatic colonic adenocarcinoma, and gastric cancer, which exhibit confirmed MUC1 positive status [132]. The gene discussed is MUC1; the disease is gastric cancer.